Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesQuanterix Corp

Quanterix Corp

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
3.02 USD 0.00(0%)
Last update at 2026-11-11T21:00:00Z
VOLUME
506770
Market Cap
128.64M

Momentum Score

…

Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, the company offers contract research and clinical laboratory testing services, including research and clinical trial testing, and lucent diagnostic services. The company primarily operates in the areas of neurology, oncology and immunology, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and sales force and distributors. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.98
Low
3.40
High
52 Week Price Range
2.15
Low
8.77
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Quanterix develops ultrasensitive digital immunoassay platforms and consumables for detecting low‑abundance protein biomarkers in research and clinical settings. Long‑term growth may be supported by rising demand for precise biomarker measurement in neurology, oncology and therapeutic development plus recurring consumable revenue. Investors may find the company attractive because its platform appears positioned to enable differentiated assays and scalable recurring sales.

Material risks include execution and commercial adoption challenges, competition from alternative assay technologies, dependence on consumable attach rates and ongoing losses that could require additional financing.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
3.02
Dividend Yield
-
Revenue TTM
153.41M
Revenue Per Share
3.28
Gross Profit TTM
68.36M
Debt / Equity
0.13
ROE
-46.49%
Net Debt
7.40M
ROCE
-32.64%
Diluted EPS TTM
-2.62

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -112.27M -38.10M -27.64M -96.64M -57.72M
Net income -107.15M -38.53M -28.35M -96.70M -57.69M
Selling general administrative 138.85M 104.64M 92.82M 1.28M 92.34M
Selling and marketing expenses - - 0.30M 92.00M -
Gross profit 64.72M 81.12M 73.00M 46.24M 61.73M
Reconciled depreciation 18.93M 8.36M 5.95M 5.35M 4.85M
Ebit -112.27M -38.10M -44.66M -72.36M -63.44M
Ebitda -93.35M -29.74M -36.37M -43.01M -58.59M
Depreciation and amortization 18.93M 8.36M 8.29M 29.35M 4.85M
Non operating income net other - - - -0.06M 1.26M
Operating income -109.81M -52.62M -45.99M -72.36M -58.59M
Other operating expenses 248.47M 188.05M 167.13M 177.31M 169.14M
Interest expense - - 15.84M 5.13M 0.40M
Tax provision -5.12M 0.43M 0.63M 0.07M -0.04M
Interest income 8.57M 14.65M 15.84M - -
Net interest income 8.57M 14.65M 14.34M 5.13M -0.40M
Non recurring - - - 29.35M -
Income tax expense -5.12M 0.43M 0.72M 0.07M -0.04M
Total revenue 138.65M 135.44M 121.14M 104.95M 110.56M
Total operating expenses 174.53M 133.74M 118.99M 118.59M 120.31M
Cost of revenue 73.94M 54.32M 48.14M 58.72M 48.83M
Total other income expense net -2.46M 14.52M 18.36M -24.28M 0.86M
Net income from continuing ops -107.15M -38.53M -38.51M -96.70M -57.69M
Net income applicable to common shares - - - -96.70M -57.69M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 418.77M 406.53M 425.01M 434.20M 501.53M
Intangible assets 131.79M 4.03M 6.03M 7.52M 10.53M
Other current assets 9.29M 9.56M 9.29M 6.86M 6.51M
Total liab 123.04M 76.50M 78.08M 75.26M 60.58M
Total stockholder equity 295.73M 330.04M 346.93M 358.94M 440.95M
Other current liab 32.55M 20.45M 19.70M 15.79M 19.98M
Common stock 0.05M 0.04M 0.04M 0.04M 0.04M
Capital stock 0.05M 0.04M 0.04M 0.04M 0.04M
Retained earnings -577.23M -470.08M -434.50M -402.16M -305.46M
Other liab - - - 2.88M 3.13M
Good will 26.38M 0.00M - 0.00M 9.63M
Other assets - - - 3.90M 2.96M
Cash 29.84M 56.71M 174.42M 338.74M 396.46M
Total current liabilities 74.76M 42.01M 38.46M 30.96M 36.98M
Current deferred revenue 20.73M 8.83M 9.47M 8.64M 6.36M
Net debt 7.40M -19.34M -132.96M -294.64M -374.57M
Short term debt 7.92M 4.76M 4.24M 2.69M 1.43M
Short long term debt total 37.24M 37.37M 41.46M 44.10M 21.89M
Other stockholder equity 873.64M 803.16M 783.14M 763.69M 745.94M
Property plant equipment - - - 20.16M 29.45M
Total current assets 212.26M 363.59M 378.39M 381.40M 448.95M
Net tangible assets - - - 358.94M 420.79M
Short term investments 88.39M 232.41M 146.90M - -
Net receivables 29.97M 32.14M 25.41M 19.02M 23.79M
Inventory 54.76M 32.77M 22.36M 16.79M 22.19M
Accounts payable 13.57M 6.95M 5.05M 3.84M 9.21M
Accumulated other comprehensive income -0.72M -3.08M -1.76M -2.62M 0.44M
Common stock total equity - - - 0.04M 0.04M
Retained earnings total equity - - - -402.16M -305.46M
Non currrent assets other 8.01M 5.42M -4.01M 3.90M 2.96M
Non current assets total 206.51M 42.94M 46.62M 52.80M 52.57M
Capital lease obligations 37.24M 37.37M 41.46M 44.10M 21.89M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 146.07M -82.27M -128.37M -11.21M -6.34M
Change to liabilities - - - -6.73M 4.57M
Total cashflows from investing activities 50.23M -82.27M -148.40M -11.21M -6.34M
Net borrowings - - 0.00M - -7.74M
Total cash from financing activities -0.71M 0.46M 2.69M 2.31M 270.80M
Change to operating activities - - - -5.71M -1.12M
Net income -107.15M -38.53M -32.33M -96.70M -57.69M
Change in cash -26.14M -117.71M -164.31M -57.70M 216.46M
Begin period cash flow 59.32M 177.03M 341.34M 399.04M 182.58M
End period cash flow 33.18M 59.32M 177.03M 341.34M 399.04M
Total cash from operating activities -77.24M -35.16M -18.90M -48.27M -47.91M
Issuance of capital stock - - 0.00M 0.00M 269.72M
Depreciation 18.93M 8.36M 8.38M 5.35M 4.85M
Other cashflows from investing activities - - - 0.52M 7.28M
Change to inventory 4.03M -6.68M -5.36M 5.39M -8.09M
Change to account receivables 10.61M -7.70M -6.70M 5.16M -6.85M
Sale purchase of stock - - -0.20M 2.31M 278.53M
Other cashflows from financing activities -1.45M -2.61M -0.20M 2.31M 8.81M
Change to netincome - - - 40.29M 16.34M
Capital expenditures 2.61M 3.37M 3.79M 11.73M 13.62M
Change receivables - - - 5.16M -6.85M
Cash flows other operating - - - -1.03M -1.04M
Cash and cash equivalents changes - - - -57.17M 216.55M
Change in working capital -2.35M -18.79M -11.80M 2.07M -12.19M
Stock based compensation 20.72M 19.99M 16.76M 15.44M 15.97M
Other non cash items -1.51M -6.19M 0.09M 25.79M 0.34M
Free cash flow -79.85M -38.53M -22.69M -60.00M -61.52M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
QTRX
Quanterix Corp		 -
-%		 3.02 - - 0.84 0.50 0.39 -1.49
ABT
Abbott Laboratories		 -1.17
1.06%		 109.29 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC		 0.02
0.02%		 101.61 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation		 -5.50
1.70%		 318.79 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG		 0.30
0.63%		 48.57 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Quanterix Corp

Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, the company offers contract research and clinical laboratory testing services, including research and clinical trial testing, and lucent diagnostic services. The company primarily operates in the areas of neurology, oncology and immunology, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and sales force and distributors. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

Building 1, Billerica, MA, United States, 01821

617 301 9400

https://www.quanterix.com

450

Name Title Year Born
Dr. Masoud Toloue Ph.D. Pres, CEO & Director 1980
Dr. David R. Walt Ph.D. Co-Founder, Chairman of Scientific Advisory Board & Independent Director 1953
Mr. Michael A. Doyle CFO & Treasurer 1956
Mr. Bruce J. Bal VP of Operations, Service & Quality 1959
Mr. Daniel Pikora Chief Operating Officer 1975
Dr. David C. Duffy Ph.D. Sr. VP of R&D and CTO 1971
David Panzerella VP of Sales NA
Dr. Mark T. Roskey Ph.D. Sr. VP of Strategic Partnerships 1960
Ms. Mary Ellen Cortizas VP of Laboratory Services & CRO NA
Dr. Masoud Toloue Ph.D. President, CEO & Director 1981

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…